258 related articles for article (PubMed ID: 31040936)
1. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.
Tomassetti S; Chen R; Dandapani S
Ther Adv Hematol; 2019; 10():2040620719841591. PubMed ID: 31040936
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging treatment options in primary mediastinal B-cell lymphoma.
Fakhri B; Ai W
Ther Adv Hematol; 2021; 12():20406207211048959. PubMed ID: 34659697
[TBL] [Abstract][Full Text] [Related]
3. Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices.
Takyar J; Raut M; Borse R; Balakumaran A; Sehgal M
Expert Rev Hematol; 2020 Mar; 13(3):275-287. PubMed ID: 31951774
[No Abstract] [Full Text] [Related]
4. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
[No Abstract] [Full Text] [Related]
5. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.
Forlenza CJ; Chadburn A; Giulino-Roth L
J Natl Compr Canc Netw; 2023 Mar; 21(3):323-330. PubMed ID: 36898366
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses].
Yu H; Wang L; Zhu HY; Wu W; Liang JH; Yin H; Fan L; Li JY; Xu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):495-499. PubMed ID: 32319385
[TBL] [Abstract][Full Text] [Related]
7. Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
Ahmed Z; Afridi SS; Shahid Z; Zamani Z; Rehman S; Aiman W; Khan M; Mir MA; Awan FT; Anwer F; Iftikhar R
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e865-e875. PubMed ID: 34330673
[TBL] [Abstract][Full Text] [Related]
8. Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions.
Chen H; Pan T; He Y; Zeng R; Li Y; Yi L; Zang H; Chen S; Duan Q; Xiao L; Zhou H
Front Oncol; 2021; 11():654854. PubMed ID: 33869061
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.
Vardhana S; Hamlin PA; Yang J; Zelenetz A; Sauter CS; Matasar MJ; Ni A; Yahalom J; Moskowitz CH
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2133-2138. PubMed ID: 29909154
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Zinzani PL; Ribrag V; Moskowitz CH; Michot JM; Kuruvilla J; Balakumaran A; Zhang Y; Chlosta S; Shipp MA; Armand P
Blood; 2017 Jul; 130(3):267-270. PubMed ID: 28490569
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplant for primary mediastinal B-cell lymphoma.
Poiré X; van Besien K
Expert Rev Hematol; 2009 Feb; 2(1):31-6. PubMed ID: 21082992
[TBL] [Abstract][Full Text] [Related]
12. Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.
Katsuya H; Suzumiya J; Kimura S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001659
[TBL] [Abstract][Full Text] [Related]
13. Primary mediastinal large B-cell lymphoma.
Savage KJ
Blood; 2022 Sep; 140(9):955-970. PubMed ID: 34496020
[TBL] [Abstract][Full Text] [Related]
14. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
Rieger M; Österborg A; Pettengell R; White D; Gill D; Walewski J; Kuhnt E; Loeffler M; Pfreundschuh M; Ho AD;
Ann Oncol; 2011 Mar; 22(3):664-670. PubMed ID: 20724576
[TBL] [Abstract][Full Text] [Related]
15. Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies.
Decruyenaere P; Giuili E; Verniers K; Anckaert J; De Grove K; Van der Linden M; Deeren D; Van Dorpe J; Offner F; Vandesompele J
Front Oncol; 2023; 13():1221471. PubMed ID: 37954086
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
de-la-Fuente C; Nuñez F; Cortés-Romera M; Franch-Sarto M; Ribera JM; Sancho JM
Hematol Oncol; 2021 Aug; 39(3):419-422. PubMed ID: 33369766
[TBL] [Abstract][Full Text] [Related]
17. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Wang Y; Wenzl K; Manske MK; Asmann YW; Sarangi V; Greipp PT; Krull JE; Hartert K; He R; Feldman AL; Maurer MJ; Slager SL; Nowakowski GS; Habermann TM; Witzig TE; Link BK; Ansell SM; Cerhan JR; Novak AJ
Blood Cancer J; 2019 Aug; 9(9):73. PubMed ID: 31471540
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
19. Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria.
Fairchild A; McCall CM; Oyekunle T; Niedzwiecki D; Champ C; McKinney M; Kelsey CR
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e464-e469. PubMed ID: 33487576
[TBL] [Abstract][Full Text] [Related]
20. Primary mediastinal lymphoma: diagnosis and treatment options.
Martelli M; Di Rocco A; Russo E; Perrone S; Foà R
Expert Rev Hematol; 2015 Apr; 8(2):173-86. PubMed ID: 25537750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
